News | January 21, 2015

Sunshine Heart's German Erlangen Site Achieves First Implant for OPTIONS HF EU Post-Market Study

Study designed to observe clinical outcomes of heart failure patients treated with C-Pulse system

Clinical trial/study, heart failure, Sunshine Heart, C-Pulse System

Image courtesy of Sunshine Heart

January 21, 2015 — Sunshine Heart Inc. announced the company's German Erlangen site for the OPTIONS-HF study has implanted its first patient with the C-Pulse(R) System for moderate to severe heart failure. Michael Weyand, M.D., professor at the University Hospital of Erlangen performed the operation, which took place on November 19, 2014. The surgical implantation procedure was successfully completed and the patient suffering from an ischemic cardiomyopathy was discharged from the hospital eight days post-surgery.

"The study results showed improvement of heart failure symptoms without the patient requiring anticoagulation medication for the device. Furthermore, we preserve the option for a VAD implantation or heart transplant,” commented Daniel Bujnoch, resident of the Cardiac Surgery Department of the University Hospital of Erlangen.

This marks the 12th implantation of the CE marked C-Pulse System across fourteen activated EU centers participating in the OPTIONS HF post-market surveillance clinical study.

The OPTIONS HF study is a post-market, multi-center, prospective, open label study that will include 50 patients in up to 15 European centers. The study is designed to observe clinical outcomes of heart failure patients treated with the C-Pulse system. The primary endpoint is comparable to the COUNTER HF study as it evaluates the rate of re-hospitalization due to worsening heart failure and heart failure related death in addition to many other traditional heart failure endpoints.

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counterpulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient's current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from the feasibility study, some patients treated with the C-Pulse System will be able to stop using the device due to sustained improvement in their conditions as a result of the therapy.

For more information: www.sunshineheart.com

 

 

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Overlay Init